Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32

Benzinga Newsdesk www.benzinga.com Negative 45.9%

Neg 45.9% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $33 to $32.